AtriCure (ATRC) Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATRC shares.
View ATRC analyst ratings or view top-rated stocks.

5 Wall Street research analysts have issued twelve-month target prices for AtriCure's stock. Their ATRC share price forecasts range from $56.00 to $74.00. On average, they predict the company's stock price to reach $65.00 in the next year. This suggests a possible upside of 48.4% from the stock's current price.
View analysts price targets for ATRC or view top-rated stocks among Wall Street analysts.

AtriCure's stock was trading at $44.38 on January 1st, 2023. Since then, ATRC stock has decreased by 1.3% and is now trading at $43.80.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our ATRC earnings forecast.

AtriCure, Inc. (NASDAQ:ATRC) released its earnings results on Tuesday, July, 25th. The medical device company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.15. The medical device company had revenue of $100.92 million for the quarter, compared to analyst estimates of $97.55 million. AtriCure had a negative trailing twelve-month return on equity of 7.11% and a negative net margin of 7.67%. The company's revenue for the quarter was up 19.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.32) EPS.

ETFs with the largest weight of AtriCure (NASDAQ:ATRC) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Nuveen Small Cap Select ETF (NSCS), Simplify Health Care ETF (PINK), Harbor Corporate Culture Small Cap ETF (HAPS), Principal Healthcare Innovators ETF (BTEC) and Invesco Nasdaq Future Gen 200 ETF (QQQS).iShares U.S. Medical Devices ETF (IHI).

AtriCure issued an update on its FY 2023 earnings guidance on Tuesday, July, 25th. The company provided EPS guidance of -$0.94--$0.92 for the period, compared to the consensus EPS estimate of -$1.02. The company issued revenue guidance of $392.00 million-$395.00 million, compared to the consensus revenue estimate of $388.31 million.

38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Gilead Sciences (GILD), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Enterprise Products Partners (EPD), Abbott Laboratories (ABT), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Pfizer (PFE) and Sarepta Therapeutics (SRPT).

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ATRC stock can currently be purchased for approximately $43.80.

AtriCure (NASDAQ:ATRC) has a market capitalization of $2.08 billion and generates $330.38 million in revenue each year. The medical device company earns $-46,470,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

The company employs 1,050 workers across the globe.

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The official website for the company is www.atricure.com. The medical device company can be reached via phone at (513) 755-4100, via email at lynn@gilmartinir.com, or via fax at 513-755-4567.